Immunotherapy in Locally Advanced HNSCC: Is There Still Room for New Agents?
In June 2025 the FDA approved MSD’s Keytruda (pembrolizumab) for resectable locally advanced head‑and‑neck squamous cell carcinoma (LA HNSCC) with PD‑L1 CPS ≥ 1, based on the KEYNOTE‑689 trial. A separate adjuvant nivolumab study (NIVOPOSTOP) showed promising results, though regulatory filing is pending. Approximately 63,000 LA HNSCC cases were diagnosed in 2024 across the US and major European markets, but current immuno‑oncology regimens cover only surgical patients, leaving large non‑surgical and older cohorts untreated. The data expose gaps—especially for patients receiving definitive chemoradiotherapy, those over 65, and PD‑L1‑low tumors—creating a sizable opportunity for new agents.
STAT+: Gene Therapy Trial for Deafness Adds Evidence to Drug’s Efficacy
Researchers have reported that a gene‑therapy injection dramatically improved hearing in a Chinese clinical trial, with 90% of participants noting significant gains. The study, published in Nature, includes both children and adults, such as a 32‑year‑old who regained functional hearing....
Synthetic Smart Proteins that Function as Biological Switches
Researchers at Queensland University of Technology have used artificial‑intelligence design to create synthetic proteins that function as programmable biological switches. The engineered proteins combine receptor and reporter domains, enabling them to detect small molecules, peptides or nucleic acids and generate...
The META-AF Trial
Researchers launched the META‑AF trial to evaluate metformin as an adjunct to catheter ablation in atrial fibrillation patients. The study randomizes roughly 500 participants to receive metformin or placebo beginning two weeks before ablation, with follow‑up through 12 months. Primary...
AI Is Spitting Out More Potential Drugs than Ever. This Start-Up Wants to Figure Out Which Ones Matter.
10x Science, a biotech AI startup founded by former Stanford researchers, announced a $4.8 million seed round led by Initialized Capital. The company’s platform combines deterministic chemistry algorithms with AI agents to automatically interpret mass‑spectrometry data, turning raw spectra into actionable...
Deerfield Group Launches Prismatiq for Life Sciences
Deerfield Group unveiled Prismatiq, a field‑enablement platform built specifically for life‑science companies. The solution ties together brand strategy, content, data and engagement insights in a single, CRM‑compatible workspace. By tracking every content interaction, Prismatiq gives reps real‑time analytics to personalize,...
Immunotherapy Drug Helps Bladder Cancer Patients Avoid Major Organ Removal
A phase‑2 trial led by NYU Langone Health found that adding pembrolizumab (Keytruda) to standard chemotherapy, radiation, and surgery allowed 60% of patients with muscle‑invasive bladder cancer to avoid cystectomy for up to two years. The study, the largest of...
Lilly, Novo Dip as Proposed Medicare Coverage for GLP-1 Pilot Thrown Off Balance
The Centers for Medicare & Medicaid Services (CMS) has indefinitely postponed its BALANCE financing model, a pilot intended to expand Medicare coverage for GLP‑1 obesity drugs. The delay triggered a roughly 2% drop in Eli Lilly’s share price and a 4%...
INBRAIN Neuroelectronics Completes Patient Recruitment for First-in-Human Study Evaluating Its Graphene Cortical Interface
INBRAIN Neuroelectronics announced that patient recruitment is complete for its first‑in‑human trial of a graphene‑based cortical interface. Ten patients were enrolled, and eight underwent surgery without any peri‑operative device failures, yielding complete datasets. The study, run with the University of...
MSD-Backed Ray Locks in $125m to Back Eye Drug Pipeline
Ray Therapeutics announced a $125 million Series B round, led by Janus Henderson Investors with participation from Merck’s venture arm, MRL Ventures and Novo Holdings. The capital will fund late‑stage clinical work and commercial preparation for RTX‑015, its lead gene‑therapy candidate for...
Immunotherapy Offers Hope in Avoiding Bladder Removal for Cancer Patients
A new immunotherapy regimen combining checkpoint inhibitor pembrolizumab with standard chemoradiation has demonstrated a high rate of bladder preservation in patients with muscle‑invasive bladder cancer. In a multinational Phase III trial of 560 participants, 68% of patients avoided cystectomy at...
Amid US Ordeal, Moderna Wins EU Approval for Flu/COVID-19 Combo Shot
Moderna received European Commission approval for its mCOMBRIAX vaccine, a combined flu and COVID‑19 shot targeting adults 50 and older across all 27 EU members plus Iceland, Liechtenstein and Norway. The combo pairs Moderna’s next‑generation COVID vaccine mNEXSPIKE with the...
An ‘AI Scientist’ Can Tackle Drug R&D. What Does that Mean for Pharma?
AI agents are moving from analytical tools to autonomous coworkers in pharma, with Owkin’s K Pro platform acting as an “AI scientist” that can answer complex research questions in hours rather than weeks. The system pulls together literature, gene‑expression data, and...
New Data Build Case for Roche's Oral BTK Drug for MS
Roche reported that its oral BTK inhibitor fenebrutinib dramatically reduced relapse rates and MRI lesions in two phase 3 FENhance trials for relapsing multiple sclerosis, outperforming Sanofi's Aubagio. The drug cut annualised relapse rates by 51.1% and 58.5% and lowered inflammation...
Epstein-Barr Virus Methylation Aids Nasopharyngeal Cancer Screening
Researchers led by Wu, Z.C. and colleagues introduced an Epstein‑Barr virus (EBV) Cp methylation assay that triages individuals for nasopharyngeal carcinoma (NPC) risk. The method, published in Nature Communications, leverages viral DNA methylation patterns from nasopharyngeal swabs to achieve higher...
Regeneron Reports P-III (NIMBLE) Trial Data on Cemdisiran for Generalized Myasthenia Gravis (gMG)
Regeneron presented Phase III (NIMBLE) data showing that subcutaneous cemdisiran 600 mg every 12 weeks significantly improved symptoms in adults with generalized myasthenia gravis (gMG) and anti‑AChR antibodies. Over 24 weeks, the cemdisiran arm reduced MG‑ADL scores by 4.5 points versus 2.2...
Firm Perfection (Hibiscus)²
Firm Perfection (Hibiscus)² is a biotech‑driven skin‑care active that targets inflammaging by modulating chronic inflammation, restoring cellular communication, rebalancing regenerative pathways, and stimulating collagen repair. Clinical trials showed a 52% reduction in skin amplitude, delivering visibly firmer skin and improved...
Merck Steps up as 'Meaningful Competitor' To Gilead with HIV Pill Approval
Merck received FDA approval for Idvynso, a once‑daily, single‑pill regimen for virologically suppressed HIV‑1 adults, slated for U.S. launch on May 11, 2026. The drug demonstrated non‑inferior viral suppression versus continued Biktarvy use in two pivotal trials. Analysts see Idvynso...
Ajinomoto Creates New Tech to Replace One of Cultivated Meat’s Most Expensive Components
Japanese food conglomerate Ajinomoto has engineered a plant‑derived hinokitiol compound to replace transferrin, the most expensive ingredient in cultivated‑meat culture media. Transferrin accounts for roughly 95% of media costs, so the new iron‑binding molecule could slash production expenses dramatically. Hinokitiol...
New Postbiotic Biotechnology Stimulates Natural Melanin and Helps Reverse Hair Graying
Chemyunion has launched BioTech4 AntiGray, a postbiotic Lactobacillus ferment lysate that stimulates natural melanin production to reverse hair graying. Ex‑vivo tests showed a 43% increase in melanin in follicles, and a 120‑day in‑vivo study with 90 volunteers reported 76.7% saw...
FDA Approves MSD’s Once-Daily HIV Combo Idvynso
Merck’s Idvynso (doravirine/islatravir) received FDA approval, marking the first tenofovir‑free, non‑INSTI two‑drug regimen for HIV. The decision follows Phase III trials that demonstrated non‑inferior viral suppression compared with Gilead’s three‑drug standard Biktarvy. Idvynso targets virologically suppressed patients without prior treatment failure...
Ipsen’s Ojemda (Tovorafenib) Receives Conditional Approval for R/R BRAF-Altered Pediatric Low-Grade Glioma (pLGG) in the EU
Ipsen’s oral kinase inhibitor Ojemda (tovorafenib) received conditional approval from the European Commission for treating pediatric low‑grade glioma (pLGG) with BRAF fusions, rearrangements or V600 mutations. The indication applies to patients six months or older who have progressed after at...
Gene Variant, RSV Bronchiolitis Linked to Male Asthma
A new longitudinal study of 3,200 infants found that a common variant in the 17q21 locus dramatically amplifies the risk of developing asthma after early‑life respiratory syncytial virus (RSV) bronchiolitis, but only in male children. Boys carrying the risk allele...
Can Biotech Finally Fix Infertility?
Infertility affects one in six adults worldwide, yet current care relies heavily on IVF, which still yields modest pregnancy rates—33% per transfer for standard cycles and 51% for egg donation. Biotech firms are targeting the biological gaps that IVF bypasses,...
Robotic Phlebotomy Study Signals Automation Shift for Clinical Labs
Vitestro’s autonomous robotic phlebotomy system Aletta completed a multicenter ADOPT trial involving 1,633 patients, achieving a 94.5% first‑stick success rate and markedly low hemolysis (0.3%) and adverse events (0.6%). Patient surveys showed 90% experienced equal or less pain, with 82%...
The Fifteen-Year-Old Who Just Earned a PhD and Is Specialising in Immortality
Laurent Simons, a Belgian prodigy, defended a quantum‑physics PhD at just 15, becoming one of the youngest doctorate holders in history. Within weeks he relocated to Munich to begin a second doctorate that fuses medical science with artificial intelligence, aiming...
Rapid Blood Infection Test Fails to Improve Survival
A large, open‑label randomized trial of 899 patients with gram‑negative bacteremia compared rapid antimicrobial susceptibility testing directly from positive blood cultures to standard sub‑culture testing. The rapid approach delivered susceptibility results in about 7.5 hours versus 44 hours for the conventional method,...
New Nanomedicine Approach Boosts Chemotherapy And Immune Activity In Pancreatic Cancer
A preclinical mouse study published in Advanced Science demonstrates that photoactivatable multi‑inhibitor liposomes (PMILs) can deliver irinotecan directly to pancreatic ductal adenocarcinoma (PDAC) tumors when activated by light. The regimen combines minocycline‑mediated DNA‑repair inhibition, photodynamic priming, and localized chemotherapy, boosting...
BioAegis and Prenosis Partner for Inflammatory Disease Therapies
BioAegis Therapeutics has teamed up with AI‑focused startup Prenosis to accelerate precision‑medicine approaches for inflammatory diseases. The partnership will analyze biospecimens from BioAegis’s Phase II BTI‑203 trial of recombinant human plasma gelsolin in 600 ARDS patients across Europe, Canada and the...
Medicare Obesity Drug Pilot Extended After Insurer Pushback
The Trump administration has pushed back the start of the Medicare GLP‑1 Bridge pilot by a year after insurers fell short of the 80% enrollment target. The federal government will continue to cover drugs such as Novo Nordisk’s Wegovy, Eli Lilly’s...
Seeing Is Believing: Smart Probes Reveal Proteins Inside Living Cells with Unprecedented Clarity
Scientists at Albert Einstein College of Medicine and the Salk Institute introduced VIS‑Fb, a new class of fluorescent nanobody probes that light up only when bound to specific proteins, dramatically cutting background noise. The probes degrade when unbound, achieving up...
Amazon Just Put the Biggest Trade of the Decade on the Wrong Side—And Big Pharma Is Paying for It
Amazon has launched a direct‑to‑patient pricing model for GLP‑1 drugs, offering cash‑pay rates of $25 per month for insured patients, $149 for oral pills and $299 for injectables such as Wegovy and Zepbound. The pricing, combined with same‑day delivery to...
Emulsion Gel for Intestine‐Specific Enzyme‐Triggered Release of Probiotics
Researchers have created a water‑in‑oil jammed Pickering emulsion gel (JPEG) that encapsulates probiotics, protecting them from the acidic environment of the stomach and releasing them only in the intestine. The probiotics‑loaded JPEG (PL‑JPEG) exhibits shear‑thinning behavior, high stability against pH,...
On‐Chip Evaluation of Red Blood Cell Deformability Through Transit Velocity Index in Hematological Diseases
Researchers have introduced a microfluidic platform that measures red blood cell (RBC) deformability using a transit velocity index (V^ε=0.5) derived from capillary‑like constrictions. The index reliably tracks stiffness changes when RBCs are chemically stiffened with diamide, confirming its sensitivity. Applying...
Genentech Reports the P-III (METEOROID) Trial Data on Enspryng (Satralizumab) to Treat MOGAD
Genentech presented Phase III METEOROID trial results for Enspryng (satralizumab) in patients aged 12 and older with myelin oligodendrocyte glycoprotein antibody‑associated disease (MOGAD). The study met its primary endpoint, showing 87% of participants remained relapse‑free at 48 weeks versus 67%...
Artera’s Prostate Biopsy and Breast Cancer Assays Receive CE Mark
Artera announced that its ArteraAI prostate biopsy and breast cancer assays have received CE marking under the EU In Vitro Diagnostic Regulation, expanding the company’s reach to the European market. The prostate assay is the first AI‑enabled prognostic and predictive test...
PARP Inhibitors: A Proven Class Facing Limits
PARP inhibitors have reshaped treatment for BRCA‑mutated cancers by exploiting synthetic lethality, but their expansion beyond this niche faces hurdles. While ovarian, breast, pancreatic, and prostate indications now include PARP‑based maintenance or combination regimens, inconsistent benefits in HRD‑positive and broader...
The Definitive Infrastructure for Modern Drug Development
Paradigm Health has launched an AI‑powered clinical research platform that operates across a national network of more than 800 community and academic sites in the United States, Japan and Israel. The platform embeds trial design, patient identification and data capture...
Roche Reports Phase III METEOROID Study Results for MOGAD
Roche announced that its subcutaneous antibody satralizumab, marketed as Enspryng, achieved a 68% reduction in relapse risk in the Phase III METEOROID trial for myelin oligodendrocyte glycoprotein antibody‑associated disease (MOGAD). At 48 weeks, 87% of patients on Enspryng remained relapse‑free versus...
Sanofi Reports the US FDA Approval of Tzield to Delay Onset of Stage 3 Type 1 Diabetes in Children (≥1years)
Sanofi’s monoclonal antibody Tzield (teplizumab‑mzwv) received U.S. FDA approval under priority review to delay the onset of stage 3 type 1 diabetes (T1D) in children as young as one year who are diagnosed with stage 2 disease. The decision was driven by one‑year...
Lentinan‐Enhanced Mn3O4 Nanoparticles for Neuroinflammation Relief and Parkinson's Disease Treatment
Researchers have engineered a lentinan‑coated manganese oxide (Mn3O4@LNT) nanoparticle that can circulate long‑term and cross the blood‑brain barrier (BBB). Proteomic analysis revealed that the LNT coating reshapes the particle’s protein corona, enhancing BBB traversal and brain accumulation. In cellular and...
Epoch to Open World’s Largest Nylon Biorecycling Plant
Epoch Biodesign, a UK biotech specializing in enzymatic recycling, will launch the world’s largest nylon 6,6 biorecycling demonstration plant at Imperial College London’s Grapht Works hub. The facility, slated for the third quarter of 2026, aims to process hundreds of tonnes of...
Roche’s Fenebrutinib Cuts Relapses in MS Amid Safety Concerns
Roche’s investigational BTK inhibitor fenebrutinib achieved 51.1% and 58.5% reductions in annualised relapse rates versus teriflunomide in the Phase III FENhance 1 and 2 trials for relapsing multiple sclerosis, while also cutting MRI lesion activity. The drug showed encouraging trends in disability‑progression measures...
Merck Reports the US FDA Approval of Idvynso for Virologically Suppressed HIV-1 Infection
Merck’s Idvynso, a once‑daily tablet combining 100 mg doravirine with 0.25 mg islatravir, received FDA approval as a switch regimen for virologically suppressed HIV‑1 adults. The approval rests on two Phase III trials—Trial 052 (n=513) and Trial 051 (n=551)—which demonstrated comparable viral suppression to existing...
Hypoallergenicity of a Hydrolyzed Rice Protein-Based Formula Containing 2-Fucosyllactose and Lacto-N-Neotetraose in Children with Cow’s Milk Allergy: Protocol for a...
The RIGHT‑HY study is a multicenter, double‑blind, crossover trial evaluating a hydrolyzed rice protein formula enriched with the human milk oligosaccharides 2‑fucosyllactose and lacto‑N‑neotetraose (HRF‑HMO) in children aged 60 days to 3 years with IgE‑mediated cow’s milk allergy (CMA). Up to 67...
Lupin Launches Generic Diabetes Drug in US After USFDA Approval
Indian pharma Lupin Ltd received FDA approval for its generic dapagliflozin‑metformin extended‑release tablets and launched them in the United States. The product matches the brand Xigduo XR in bioequivalence and is offered in four strength combinations. The launch adds a lower‑cost...
From Brain Implant to Lifelong Companion: Michel Maharbiz Unveils Epia Neuro
Epia Neuro, a stealth‑mode neurotechnology startup co‑founded by Michel Maharbiz, announced its public debut at the Bioelectronic Medicine Forum. The company, now 45‑strong and backed by venture and pharma investors, is developing a skull‑mounted, dura‑sparing neural interface designed for outpatient...
Two Drugs Stir Hope for Treatment of Deadly Pancreatic Cancer
Two experimental treatments presented at a San Diego cancer conference have shown early signs of efficacy against pancreatic cancer, a disease that kills more than 50,000 Americans each year. The data come from small, unpublished trials and the drugs have not...
SynbioTech's L. Plantarum FS4722 Emerges as a Potential Preventive Approach for Hyperuricemia
SynbioTech announced that its probiotic Lactiplantibacillus plantarum FS4722 markedly lowers serum uric acid in mouse models, matching the efficacy of conventional uric‑lowering drugs while showing no kidney toxicity. The strain works through a multi‑mechanism gut‑liver‑kidney axis: it reduces intestinal purine...
Multi-Regional Trials Have yet to Become the Norm
BioCentury’s website outlines a comprehensive cookie policy that categorises cookies into strictly necessary, functional, marketing, advertising, and analytics types. Strictly necessary cookies are always active and essential for authentication and site navigation, while functional cookies enable enhanced personalization. Marketing and...